Abzena is exhibiting at the upcoming PBSS San Diego workshop on July 23rd: “Why All These New Modalities?”

The event plans to cover:

a) Many new drug modalities/platforms have appeared in the recent past
b) Good targets are hard to find and many are considered ‘undruggable’
c) Diversity of Modalities expands druggable target space,
d) Diversity of Modalities increase probability of technical success in drug discovery

Our team of experts including Dr Parviz Shamlou, our SVP of Science & Technology, and VP of Business Development, Dr Craig Magee, will be on hand to hear about your complex biologics or bioconjugate program’s needs.  Swing by our tabletop to connect with our team and hear how Abzena can help rapidly move your biopharmaceutical forward from discovery through commercial launch.

With decades of experience in designing, developing, and manufacturing antibody and antibody-drug conjugate (ADCs) programs, our team leverages deep scientific and technical know-how to bring compounds to market- finding the best solutions and technologies to achieve the best project outcome.